Dr. Ryan Zarychanski
Before the pandemic, hematologist and critical care physician Dr. Ryan Zarychanski already had a well-established clinical practice and research program…
Before the pandemic, hematologist and critical care physician Dr. Ryan Zarychanski already had a well-established clinical practice and research program…
Before the pandemic, hematologist and critical care physician Dr. Ryan Zarychanski already had a well-established clinical practice and research program. When COVID-19 first arrived, he and his team diverted all of their clinical research infrastructure to quickly investigate potential new treatments for the disease. His work has been groundbreaking at a global level, both in the actual treatment options identified and the process he developed to identify them.
During the early days of the pandemic and lockdowns that disrupted clinical and research operations around the world, Dr. Zarychanski built a global network of researchers and developed collaborative processes to rapidly study the effectiveness of potential treatments for COVID-19. Within the first year, he and the team had multiple publications in the New England Journal of Medicine communicating research findings that changed how COVID-19 is treated around the world. Their work identified treatments that save lives and reduce disease progress, like steroids, IL‑6 antagonists and therapeutic-dose heparin, while also ruling out potential therapies that were ineffective, like hydroxychloroquine.
With increased reports of thrombosis and inflammation from COVID-19 infection, Dr. Zarychanski . quickly and collaboratively, developed, led, and launched a multinational trial to evaluate therapeutic-dose heparin in hospitalized COVID-19 patients. With the help of provincial catalyst funding, in a few short weeks, the team raised close to $10 million to fund the trial. Eight months later over 3,000 patients were enrolled from 121 hospitals in 104 countries. The trial found that therapeutic-dose heparin, an inexpensive and widely available drug, improved survival and reduced ICU admissions by minimizing infection progression. They simultaneously identified that therapeutic-dose heparin was not beneficial when given to critically ill patients or those on organ support. To complete the trials in a timeframe that would meaningfully inform the pandemic, the team developed a new type of randomized trial which has come to be known as the multiplatform RCT (mpRCT), which has been adopted widely by other clinical trial groups. The methods developed will speed the completion of clinical trials and foster global collaboration in medicine for years to come
As one of Manitoba’s most impactful clinician-scientists, Dr. Zarychanski and team are recognized for discovering 1 of only 4 therapies routinely given to patients hospitalized for COVID-19. Administration of therapeutic-dose heparin in COVID-19 has had the potential to prevent hundreds of thousands of ICU admissions and thousands of deaths around the world.
Dr. Zarychanski continues to grow his local team of clinician-scientists and researchers and has supported faculty colleagues with numerous opportunities to lead large national trials. He is training a new generation of clinician-scientists to lead future practice-changing trials and helping to create a new paradigm for clinical medicine in Manitoba where clinical trials are embedded within clinical care as part of a learning health system.